Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CALCA | P06881 | 5/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069367 | 0.84 | ATM (0.42) | ATMEGLN1POLBALDH1A1L3MBTL1 | |
| SCHEMBL4059321 | 0.83 | EGLN1 (0.51) | CALCAEGLN1POLBL3MBTL1LMNA | |
| SCHEMBL4063922 | 0.83 | CALCA (0.48) | CALCAEGLN1POLBL3MBTL1LMNA | |
| SCHEMBL13813016 | 0.82 | EGLN1 (0.50) | CALCAEGLN1POLBALDH1A1L3MBTL1 | |
| SCHEMBL6498988 | 0.81 | EGLN1 (0.49) | CALCAEGLN1POLBL3MBTL1LMNA | |
| SCHEMBL4062668 | 0.81 | CALCA (0.49) | CALCAEGLN1POLBL3MBTL1LMNA | |
| SCHEMBL4059838 | 0.81 | CALCA (0.47) | CALCAEGLN1POLBALDH1A1L3MBTL1 | |
| SCHEMBL4062302 | 0.81 | ADORA2A (0.52) | ATMCALCAEGLN1L3MBTL1ADORA2A | |
| SCHEMBL4060321 | 0.80 | MAPK8 (0.49) | CALCAEGLN1 | |
| SCHEMBL4066438 | 0.80 | CALCA (0.47) | CALCAEGLN1POLBL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | claimed |
| US-6921759-B2 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-26 | — | — | US | claimed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | claimed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | ANTHONY NEVILLE J (US) | 2005-08-11 | — | — | US | disclosed |
| US-6921759-B2 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | disclosed |
| WO-2002030931-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | ATM 3969/4885CALCA 3366/4885EGLN1 2027/4885 |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | ATM 3969/4885CALCA 3366/4885EGLN1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.